Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | LPO | P22079 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071648 | 1.00 | FDPS (0.42) | FDPSTLR7MEN1KMT2AFNTA | |
| SCHEMBL12471754 | 0.98 | FDPS (0.44) | FDPSTLR7MEN1KMT2AFNTA | |
| SCHEMBL5032007 | 0.92 | FDPS (0.45) | FDPSTLR7MEN1KMT2AFNTA | |
| Bromide SCHEMBL18941396 | 0.91 | FDPS (0.44) | FDPSTLR7MEN1KMT2AFNTA | |
| Hydrochloric Acid SCHEMBL2939806 | 0.91 | FDPS (0.44) | FDPSTLR7MEN1KMT2AFNTA | |
| SCHEMBL2395476 | 0.90 | FDPS (0.44) | FDPSTLR7MEN1KMT2AFNTA | |
| SCHEMBL2399728 | 0.90 | FDPS (0.44) | FDPSTLR7MEN1KMT2AFNTA | |
| SCHEMBL2393253 | 0.90 | FDPS (0.44) | FDPSTLR7MEN1KMT2AFNTA | |
| SCHEMBL7152443 | 0.90 | FDPS (0.44) | FDPSTLR7MEN1KMT2AFNTA | |
| Nitric Acid SCHEMBL16700057 | 0.89 | FDPS (0.39) | FDPSTLR7MEN1KMT2AFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128828-A1 | METHODS OF SOLVENT DISPLACEMENT FOR METAL-CONTAINING IONIC LIQUIDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250196021-A1 | METHODS OF SOLVENT DISPLACEMENT FOR METAL-CONTAINING IONIC LIQUIDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2025-06-19 | — | — | US | claimed |
| CN-107427758-B | Separation using ionic liquid solvents | 切弗朗菲利浦化学公司 | 2020-11-20 | — | — | CN | claimed |
| US-10227274-B2 | Separations with ionic liquid solvents | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2019-03-12 | — | — | US | claimed |
| EP-3244987-A1 | SEPARATIONS WITH IONIC LIQUID SOLVENTS | Chevron Phillips Chemical Company LP (US) | 2017-11-22 | — | — | EP | claimed |
| US-20150133711-A1 | Separations With Ionic Liquid Solvents | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2015-05-14 | — | — | US | claimed |
| US-20260015304-A1 | METAL-CONTAINING IONIC LIQUIDS WITH REDUCED VISCOSITY | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2026-01-15 | — | — | US | disclosed |
| US-12441671-B2 | Metal-containing ionic liquids with reduced viscosity | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-10-14 | — | — | US | disclosed |
| US-12365647-B2 | Method for preparing acrylonitrile dimer | LG CHEM, LTD. (KR) | 2025-07-22 | — | — | US | disclosed |
| WO-2025128828-A1 | METHODS OF SOLVENT DISPLACEMENT FOR METAL-CONTAINING IONIC LIQUIDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250196021-A1 | METHODS OF SOLVENT DISPLACEMENT FOR METAL-CONTAINING IONIC LIQUIDS | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2025-06-19 | — | — | US | disclosed |
| EP-3507346-B1 | ALKYLATION OF REFINERY PENTENES WITH ISOBUTANE | CHEVRON USA INC (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4511154-A1 | METAL-CONTAINING IONIC LIQUIDS WITH REDUCED VISCOSITY | Chevron Phillips Chemical Company LP (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-3244987-A1 | SEPARATIONS WITH IONIC LIQUID SOLVENTS | Chevron Phillips Chemical Company LP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9822046-B1 | Farnesane alkylation | CHEVRON U.S.A. INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9802186-B2 | Reactor for homogeneous regeneration of spent ionic liquid | CHEVRON U.S.A. INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170216827-A1 | REGENERATION OF ACIDIC IONIC LIQUID WITHOUT ADDITION OF A HYDROGENATION CATALYST | CHEVRON U.S.A. INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170216828-A1 | REACTOR FOR HOMOGENEOUS REGENERATION OF SPENT IONIC LIQUID | CHEVRON U.S.A. INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2017132016-A1 | REGENERATION OF ACIDIC IONIC LIQUID WITHOUT ADDITION OF A HYDROGENATION CATALYST | CHEVRON U.S.A. INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20150133711-A1 | Separations With Ionic Liquid Solvents | CHEVRON PHILLIPS CHEMICAL COMPANY LP | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216827-A1 | REGENERATION OF ACIDIC IONIC LIQUID WITHOUT ADDITION OF A HYDROGENATION CATALYST | MGMT, GIGYF2, PUF60 | FDPS 4143/4885TLR7 1631/4885MEN1 3328/4885 |
| US-12365647-B2 | Method for preparing acrylonitrile dimer | ADH1C, ADH1A, PUF60 | FDPS 922/4885TLR7 3068/4885MEN1 1928/4885 |
| US-20260015304-A1 | METAL-CONTAINING IONIC LIQUIDS WITH REDUCED VISCOSITY | EXOC3, ELL, IGF2BP2 | FDPS 4457/4885TLR7 2688/4885MEN1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.